ReviewScientifica2014
Phage therapy: eco-physiological pharmacology.
Review in Scientifica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 55 citations in OpenAlex.
- Broth Optical Density-Based Assessment for Phage Therapy: Turbidity Reduction, Antibacterial Virulence, and Time-Kill.Viruses · 2026Review
- CRISPR-Cas opens a new era of antimicrobial therapy as a powerful gene editing tool.World journal of microbiology & biotechnology · 2025Review
- Characterization of novel bacteriophage PSKP16 and its therapeutic potential against β-lactamase and biofilm producer strain of K2-Hypervirulent Klebsiella pneumoniae pneumonia infection in mice model.BMC microbiology · 2023Article
- Effects of bacteriophage on Salmonella Enteritidis infection in broilers.Scientific reports · 2023Article
- Phenotypic Characterization and Comparative Genomic Analysis of NovelInternational journal of molecular sciences · 2023Article
- Effects of bacteriophage supplement on the growth performance, microbial population, and PGC-1α and TLR4 gene expressions of broiler chickens.Scientific reports · 2022Article
- Further Considerations on How to Improve Phage Therapy Experimentation, Practice, and Reporting: Pharmacodynamics Perspectives.PHAGE (New Rochelle, N.Y.) · 2022Review
- Comparative Analysis ofAntibiotics (Basel, Switzerland) · 2021Article
- The Age of Phage: Friend or Foe in the New Dawn of Therapeutic and Biocontrol Applications?Pharmaceuticals (Basel, Switzerland) · 2021Review
- Evaluation of Phage Therapy for Pulmonary Infection of Mouse by Liquid Aerosol-ExposureInfection and drug resistance · 2021Article
- vB-ApyS-JF1, the FirstFrontiers in microbiology · 2021Article
- Phage Biocontrol of Campylobacter: A One Health Approach.Current topics in microbiology and immunology · 2021Review
- Nanotechnology Based Approaches in Phage Therapy: Overcoming the Pharmacological Barriers.Frontiers in pharmacology · 2021Review
- Phage-Mediated Control ofFrontiers in microbiology · 2021Article
- Editorial: Bacteriophages Isolation From the Environment and Their Antimicrobial Therapeutic Potential.Frontiers in microbiology · 2021Article
- Phage therapy for severe bacterial infections: a narrative review.The Medical journal of Australia · 2020Review
- Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.Microbiology and molecular biology reviews : MMBR · 2019Review
- Phage-Antibiotic Combination Treatments: Antagonistic Impacts of Antibiotics on the Pharmacodynamics of Phage Therapy?Antibiotics (Basel, Switzerland) · 2019Review
- Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review.Medicinal research reviews · 2019Review
- Recent advances in the treatment ofInfection and drug resistance · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial virus use as antibacterial agents, in the guise of what is commonly known as phage therapy, is an inherently physiological, ecological, and also pharmacological process. Physiologically we can consider metabolic properties of phage infections of bacteria and variation in those properties as a function of preexisting bacterial states. In addition, there are patient responses to pathogenesis, patient responses to phage infections of pathogens, and also patient responses to phage virions alone. Ecologically, we can consider phage propagation, densities, distribution (within bodies), impact on body-associated microbiota (as ecological communities), and modification of the functioning of body "ecosystems" more generally. These ecological and physiological components in many ways represent different perspectives on otherwise equivalent phenomena. Comparable to drugs, one also can view phages during phage therapy in pharmacological terms. The relatively unique status of phages within the context of phage therapy as essentially replicating antimicrobials can therefore result in a confluence of perspectives, many of which can be useful towards gaining a better mechanistic appreciation of phage therapy, as I consider here. Pharmacology more generally may be viewed as a discipline that lies at an interface between organism-associated phenomena, as considered by physiology, and environmental interactions as considered by ecology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.